Related references
Note: Only part of the references are listed.CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity
Cheng-Jung Lai et al.
CANCER RESEARCH (2010)
Inhibition of SIRT1 deacetylase suppresses estrogen receptor signaling
Yuan Yao et al.
CARCINOGENESIS (2010)
Myocyte Enhancer Factor 2 and Class II Histone Deacetylases Control a Gender-Specific Pathway of Cardioprotection Mediated by the Estrogen Receptor
Eva van Rooij et al.
CIRCULATION RESEARCH (2010)
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
Jiahuai Tan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2010)
Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer
Xiong Cai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Histone Deacetylase 7 and FoxA1 in Estrogen-Mediated Repression of RPRM
Simeen Malik et al.
MOLECULAR AND CELLULAR BIOLOGY (2010)
Valproic acid restores ERα and antiestrogen sensitivity to ERα-negative breast cancer cells
N. Fortunati et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2010)
HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy
Omar Khan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells
Qun Zhou et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker
P. N. Munster et al.
BRITISH JOURNAL OF CANCER (2009)
Biomarkers for predicting clinical responses to HDAC inhibitors
Lindsay Stimson et al.
CANCER LETTERS (2009)
HDAC expression and clinical prognosis in human malignancies
Wilko Weichert
CANCER LETTERS (2009)
Isoform-specific histone deacetylase inhibitors: The next step?
Sriram Balasubramanian et al.
CANCER LETTERS (2009)
HDAC family: What are the cancer relevant targets?
Olaf Witt et al.
CANCER LETTERS (2009)
Association of Estrogen Receptor α and Histone Deacetylase 6 Causes Rapid Deacetylation of Tubulin in Breast Cancer Cells
Kotaro Azuma et al.
CANCER RESEARCH (2009)
Interaction of TFAP2C with the Estrogen Receptor-alpha Promoter Is Controlled by Chromatin Structure
George W. Woodfield et al.
CLINICAL CANCER RESEARCH (2009)
Protein Acetylation and Histone Deacetylase Expression Associated with Malignant Breast Cancer Progression
Junko Suzuki et al.
CLINICAL CANCER RESEARCH (2009)
Vorinostat Inhibits Brain Metastatic Colonization in a Model of Triple-Negative Breast Cancer and Induces DNA Double-Strand Breaks
Diane Palmieri et al.
CLINICAL CANCER RESEARCH (2009)
Estrogen Regulation of MicroRNA Expression
Carolyn M. Klinge
CURRENT GENOMICS (2009)
Novel Structural Insights into Class I and II Histone Deacetylases
Ralf Ficner
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2009)
Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status
Lorena Travaglini et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer
Shundong Cang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2009)
Design of Chimeric Histone Deacetylase- and Tyrosine Kinase-Inhibitors: A Series of Imatinib Hybrides as Potent Inhibitors of Wild-Type and Mutant BCR-ABL, PDGF-Rβ, and Histone Deacetylases
Siavosh Mahboobi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
Xiaolan Hu et al.
MOLECULAR CANCER RESEARCH (2009)
Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice
Sharmila Shankar et al.
MOLECULAR CANCER THERAPEUTICS (2009)
The many roles of histone deacetylases in development and physiology: implications for disease and therapy
Michael Haberland et al.
NATURE REVIEWS GENETICS (2009)
CYP2D6 and tamoxifen: DNA matters in breast cancer
Janelle M. Hoskins et al.
NATURE REVIEWS CANCER (2009)
Histone deacetylase inhibitor SAHA induces ERα degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling
Xin Yi et al.
BIOCHEMICAL PHARMACOLOGY (2008)
A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling
P. K. Julka et al.
BRITISH JOURNAL OF CANCER (2008)
The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis
Yi-Shan Lee et al.
CANCER RESEARCH (2008)
Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling
Elona Bicaku et al.
CANCER RESEARCH (2008)
Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer
Yuri Nikolsky et al.
CANCER RESEARCH (2008)
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma
Leigh Ellis et al.
CLINICAL CANCER RESEARCH (2008)
A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study
Thehang H. Luu et al.
CLINICAL CANCER RESEARCH (2008)
An Inactivating Mutation in HDAC2 Leads to Dysregulation of Apoptosis Mediated by APAF1
Christin L. Hanigan et al.
GASTROENTEROLOGY (2008)
High-resolution genomic and expression analyses of copy number alterations in breast tumors
Peter M. Haverty et al.
GENES CHROMOSOMES & CANCER (2008)
Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity
Anja Schuetz et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
ERα negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor
Jiang Fan et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2008)
Specific Activity of Class II Histone Deacetylases in Human Breast Cancer Cells
Vanessa Duong et al.
MOLECULAR CANCER RESEARCH (2008)
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men
Xiang-Jiao Yang et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist
Ailsa J. Frew et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells
Leslie Hodges-Gallagher et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
A stromal gene signature associated with inflammatory breast cancer
Brenda J. Boersma et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Predicting features of breast cancer with gene expression patterns
Xuesong Lu et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines
T. J. Walton et al.
PROSTATE (2008)
Trichostatin A and 5 Aza-2′ deoxycytidine decrease estrogen receptor mRNA stability in ER positive MCF7 cells through modulation of HuR
Peter Pryzbylkowski et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells
Maxy De Los Santos et al.
ENDOCRINE-RELATED CANCER (2007)
Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex
Alessandro Vannini et al.
EMBO REPORTS (2007)
Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-α levels and transcriptional activity:: A result of hyperacetylation and inhibition of chaperone function of heat shock protein 90
Warren Fiskus et al.
CLINICAL CANCER RESEARCH (2007)
Histone deacetylase inhibitors: molecular mechanisms of action
W. S. Xu et al.
ONCOGENE (2007)
Estrogen receptors:: How do they signal and what are their targets
Nina Heldring et al.
PHYSIOLOGICAL REVIEWS (2007)
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series
Christine Desmedt et al.
CLINICAL CANCER RESEARCH (2007)
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity
Lao H. Saal et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Unraveling the mechanisms of endocrine resistance in breast cancer: New therapeutic opportunities
Suleiman Massarweh et al.
CLINICAL CANCER RESEARCH (2007)
High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer
Suet F. Chin et al.
GENOME BIOLOGY (2007)
Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation
Qun Zhou et al.
CANCER BIOLOGY & THERAPY (2007)
Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug
Paul A. Marks et al.
NATURE BIOTECHNOLOGY (2007)
SirT1 modulates the estrogen-insulin-like growth factor-1 signaling for postnatal development of mammary gland in mice
Hongzhe Li et al.
BREAST CANCER RESEARCH (2007)
Histone deacetylase inhibitors: Signalling towards p21(cip1/waf1)
Matthias Ocker et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2007)
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies
Koei Chin et al.
CANCER CELL (2006)
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer
Anna V. Ivshina et al.
CANCER RESEARCH (2006)
Post-translational modifications of steroid receptors
H. Faus et al.
BIOMEDICINE & PHARMACOTHERAPY (2006)
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
Kenneth R. Hess et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prognosis and gene expression profiling of 20q13-amplified breast cancers
Christophe Ginestier et al.
CLINICAL CANCER RESEARCH (2006)
Acetylation of estrogen receptor α by p300 at lysines 266 and 268 enhances the deoxyribonucleic acid binding and transactivation activities of the receptor
Mi Young Kim et al.
MOLECULAR ENDOCRINOLOGY (2006)
HDAC1 acetylation is linked to progressive modulation of steroid receptor-induced gene transcription
Yi Qiu et al.
MOLECULAR CELL (2006)
GCN5 acetyltransferase complex controls glucose metabolism through transcriptional repression of PGC-1α
Caries Lerin et al.
CELL METABOLISM (2006)
A modular analysis of breast cancer reveals a novel low-grade molecular signature in estrogen receptor - Positive tumors
Kun Yu et al.
CLINICAL CANCER RESEARCH (2006)
Histone deacetylase inhibitors: Multifunctional anticancer agents
Tao Liu et al.
CANCER TREATMENT REVIEWS (2006)
ERα and ERβ expression and transcriptional activity are differentially regulated by HDAC inhibitors
V Duong et al.
ONCOGENE (2006)
Histone deacetylase inhibitor, Trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells
John P. Alao et al.
MOLECULAR CANCER (2006)
Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis
C Sotiriou et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
P21-activated kinase 1 regulation of estrogen receptor-α activation involves serine 305 activation linked with serine 118 phosphorylation
SK Rayala et al.
CANCER RESEARCH (2006)
X chromosomal abnormalities in basal-like human breast cancer
AL Richardson et al.
CANCER CELL (2006)
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
AH Bild et al.
NATURE (2006)
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
S Minucci et al.
NATURE REVIEWS CANCER (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Opposite effects of histone deacetylase inhibitors on glucocorticoid and estrogen signaling in human endometrial ishikawa cells
W Rocha et al.
MOLECULAR PHARMACOLOGY (2005)
Recruitment of histone deacetylase 4 to the N-terminal region of estrogen receptor α
HY Leong et al.
MOLECULAR ENDOCRINOLOGY (2005)
Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast
ZH Zhang et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance
Y Hirokawa et al.
CANCER BIOLOGY & THERAPY (2005)
Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of Her-2
P Bali et al.
CLINICAL CANCER RESEARCH (2005)
Genes that mediate breast cancer metastasis to lung
AJ Minn et al.
NATURE (2005)
Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor α, in response to deacetylase inhibition by valproic acid and trichostatin A
G Reid et al.
ONCOGENE (2005)
HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma
TR Singh et al.
ONCOGENE (2005)
Release of methyl CpG binding proteins and histone deacetylase 1 from the estrogen receptor α (ER) promoter upon reactivation in ER-negative human breast cancer cells
D Sharma et al.
MOLECULAR ENDOCRINOLOGY (2005)
Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer
S Saji et al.
ONCOGENE (2005)
SHP represses transcriptional activity via recruitment of histone deacetylases
J Gobinet et al.
BIOCHEMISTRY (2005)
Histone deacetylase-1 and-3 protein expression in human breast cancer:: a tissue microarray analysis
CA Krusche et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Gene-expression pro-files to predict distant metastasis of lymph-node-negative primary breast cancer
YX Wang et al.
LANCET (2005)
Characterization of four autonomous repression domains in the corepressor receptor interacting protein 140
M Christian et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Recruitment of distinct chromatin-modifying complexes by tamoxifen-complexed estrogen receptor at natural target gene promoters in vivo
XF Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Histone deacetylase inhibition and estrogen receptor α levels modulate the transcriptional activity of partial antiestrogens
R Margueron et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2004)
The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor α-negative breast cancer cells to tamoxifen
ER Jang et al.
ONCOGENE (2004)
Multiple domains of the Receptor-Interacting Protein 140 contribute to transcription inhibition
A Castet et al.
NUCLEIC ACIDS RESEARCH (2004)
P21WAF1/CIP1 is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells
V Chopin et al.
ONCOGENE (2004)
Histone deacetylase inhibition and estrogen signalling in human breast cancer cells
R Margueron et al.
BIOCHEMICAL PHARMACOLOGY (2004)
Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells
S Nakata et al.
ONCOGENE (2004)
Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21waf1
V Chopin et al.
EXPERIMENTAL CELL RESEARCH (2004)
Histone deacetylase inhibitor trichostatin a represses estrogen receptor α-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines
JP Alao et al.
CLINICAL CANCER RESEARCH (2004)
Transcriptional regulation by the repressor of estrogen receptor activity via recruitment of histone deacetylases
V Kurtev et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Different gene expression patterns in invasive lobular and ductal carcinomas of the breast
HJ Zhao et al.
MOLECULAR BIOLOGY OF THE CELL (2004)
Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes
N Yoshida et al.
CANCER SCIENCE (2004)
HDAC6 expression is correlated with better survival in breast cancer
ZH Zhang et al.
CLINICAL CANCER RESEARCH (2004)
Estrogen receptor-α directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter
R Métivier et al.
CELL (2003)
Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor α
H Kawai et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Oestrogen receptor α increases p21WAF1/CIP1 gene expression and the antiproliferative activity of histone deacetylase inhibitors in human breast cancer cells
R Margueron et al.
JOURNAL OF ENDOCRINOLOGY (2003)
A novel histone deacetylase inhibitor, Scriptaid, enhances expression of functional estrogen receptor α (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine
JC Keen et al.
BREAST CANCER RESEARCH AND TREATMENT (2003)
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
C Sotiriou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Repeated observation of breast tumor subtypes in independent gene expression data sets
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
PRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-α in breast cancer
M Macaluso et al.
ONCOGENE (2003)
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases
VJ Bardou et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Gene expression predictors of breast cancer outcomes
E Huang et al.
LANCET (2003)
A gene-expression signature as a predictor of survival in breast cancer.
MJ van de Vijver et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors
JR Pollack et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Development of cDNA microarray for expression profiling of estrogen-responsive genes
A Inoue et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2002)
Molecular determinants for the tissue specificity of SERMs
YF Shang et al.
SCIENCE (2002)
Minireview:: genomic organization of the human ERα gene promoter region
M Kos et al.
MOLECULAR ENDOCRINOLOGY (2001)
Acetylation of steroidogenic factor 1 protein regulates its transcriptional activity and recruits the coactivator GCN5
AL Jacob et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Predicting the clinical status of human breast cancer by using gene expression profiles
M West et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Acetylation of nuclear hormone receptor-interacting protein RIP140 regulates binding of the transcriptional corepressor CtBP
N Vo et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3
MG Guenther et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Direct acetylation of the estrogen receptor α hinge region by p300 regulates transactivation and hormone sensitivity
CG Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Ligand-dependent formation of retinoid receptors, receptor-interacting protein 140 (RIP140), and histone deacetylase complex is mediated by a novel receptor-interacting motif of RIP140
LN Wei et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Gene-expression profiles in hereditary breast cancer.
I Hedenfalk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3
JW Li et al.
EMBO JOURNAL (2000)
p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation
MF Fu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Control of estrogen receptor ligand binding by Hsp90
AE Fliss et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2000)
Share Paper
